Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Evolus Inc EOLS

Healthcare Biotechnology
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:EOLS)

Evolus Reports Third Quarter 2025 Financial Results

Business Wire 8 days ago

Evolus to Participate in 2025 Stifel Healthcare Conference

Business Wire October 28, 2025

Evolus to Report Third Quarter Financial Results on November 5, 2025

Business Wire October 22, 2025

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 10, 2025

Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse(TM) Filler Launch

PR Newswire September 22, 2025

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 12, 2025

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

Business Wire September 8, 2025

Evolus Announces Positive Data From Pivotal Trial for Evolysse(TM) Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

Business Wire August 25, 2025

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse(TM) Sculpt Injectable Hyaluronic Acid Gel Product

Business Wire August 20, 2025
View More News ››

Opinion & Analysis (NDAQ:EOLS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:EOLS)

Using technical analysis for this stock.

It's time to be getting on-board with this one.
coolfooldumbguy - January 21, 2025

EVOLUS: NEXT BIG THING IN THE PERFORMANCE BEAUTY INDUSTRY

$EOLS Excited to share an article about Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric...
AviseAnalytics - August 4, 2023
View more Bullboard ››

Mullen Group Ltd.

Mullen Group Ltd.

Mullen Group is one of North America's largest logistics providers with a network of independently operated businesses ...
View More »